Skip to main content
OpenTrials
Completed

NCT Number: NCT03869515

Genetic Causes and Clinical Features of Childhood Interstitial Lung Diseases in China

Recruitment of a carefully characterized cohort of chILD patients, to generate a database and biobank via collecting data on chILD in China. Importantly, compatibility with ongoing United States and Europe chILD data base developments will be factored in.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Children's hospital of Fudan University

Shanghai, Shanghai Municipality, 201102, China

About this study

Children Interstitial lung disease (chILD) is a heterogeneous group of rare respiratory disorders of known and unknown etiologies that are mostly chronic and associated with high morbidity and mortality. ILD are characterized by inflammatory and fibrotic changes of the lung parenchyma structure that typically result in the presence of diffuse infiltrates on lung imaging, and abnormal pulmonary function tests with evidence of a restrictive ventilatory defect and/or impaired gas exchange.

Genetic factors are important contributors to chILD. Genetic variations have been mainly described in genes encoding (or interacting with) the surfactant proteins (SP): SP-C (SFTPC) and the ATP-binding cassette-family A-member 3 (ABCA3) (ABCA3), and less frequently in the genes encoding NKX homeobox 2 (NKX2)-1 (NKX2-1), SP-B (SFTPB), SP-A (SFTPA) ,MARS and other genes.

To investigate genetic defects and clinical features of chILD in China, wide recruitment and interdisciplinary critical peer review of all diagnoses from discharge diagnosis coding system of Children's Hospital of Fudan University will be included. Each case will be given a diagnosis independently; if no firm diagnosis is possible, the investigators will review the case periodically as new information becomes available. During the first year of the study, clinicians´ decisions according to clinical practice and outcomes will be independently monitored and assessed.

The investigators will systematically optimize and clarify the relative weight of a large spectrum of single and composite clinical outcomes, sequential limited chest CT (to minimise radiation exposure), lung function testing, histopathological categorization of lung biopsies, serum markers and genetic tests. Variability, reproducibility and the effects of training on reading images will be investigated.

This project will analyse in detail treatment and outcomes within and between subjects using data collected. Analysis of the collected data will support the definition of trial protocols planned in the future.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • The chILD syndrome exists when a child with DLD has had the common causes of DLD excluded as the primary diagnosis and has at least three of the following four criteria: (1) respiratory symptoms (e.g., cough, rapid and/or difficult breathing, or exercise intolerance);(2) respiratory signs (e.g., resting tachypnea, adventitious sounds, retractions, digital clubbing, failure to thrive, or respiratory fail- ure); (3) hypoxemia; and (4) diffuse abnormalities on CXR or a CT scan.

Exclusion criteria

  • These include cystic fibrosis, congenital or acquired immunodeficiency, congenital heart disease, bronchopulmonary dysplasia, pulmonary infection, primary ciliary dyskinesia presenting with newborn respiratory distress and recurrent aspiration.

Treatment and study plan

No intervention

Other

It's an observational study, so no intervention will be carried out.

Primary outcomes

  1. Diagnosed with specific cause for chILD

    Time frame: 6 years

    (yes/no) Specific causes for chILD based on the 2013 Official American Thoracic Society Clinical Practice Guideline: classification, evaluation, and management of childhood interstitial lung disease in infancy

Secondary outcomes

  1. Having pathogenic gene mutations

    Time frame: 6 years

    (yes/no) Genetic variations have been mainly described in genes encoding (or interacting with) the surfactant proteins (SP): SP-C (SFTPC) and the ATP-binding cassette-family A-member 3 (ABCA3) (ABCA3), and less frequently in the genes encoding NKX homeobox 2 (NKX2)-1 (NKX2-1), SP-B (SFTPB), SP-A (SFTPA) ,MARS and other genes.

  2. Hypoxemia

    Time frame: 6 years

    (yes/no) Change of PO2 in arterial blood gases from baseline when diagnosed with chILD

  3. Deterioration of pulmonary imaging

    Time frame: 6 years

    (yes/no) Change of clinical judgment on pulmonary imaging from baseline if X-ray or CT were done

  4. Change from baseline in lung function on the spirometry forced expiratory

    Time frame: 6 years

    Volume at one second (FEV1) in Liter

  5. Abnormal autoantibody at baseline when diagnosed with chILD

    Time frame: 6 years

    (yes/ no)

  6. Pathological change of lung biopsy

    Time frame: 6 years

    (yes/no) Clinical judgment on histopathological categorization of lung biopsy when diagnosed with chILD

  7. Deterioration of pulmonary arterial hypertension

    Time frame: 6 years

    (yes/no) Change of pulmonary artery pressure from baseline in echocardiagraphy

  8. Change of BALF(bronchoalveolar lavage fluid)

    Time frame: 6 years

    (yes/no) Cytology analysis on BALF at the baseline when diagnosed with chILD

  9. Survival

    Time frame: 1 years

    (yes/no)

  10. Survival

    Time frame: 2 years

    (yes/no)

  11. Survival

    Time frame: 5 years

    Five-year

  12. Abnormal thyroid hormone at baseline when diagnosed with chILD

    Time frame: 6 years

    (yes/no)

  13. Abnormal myocardial zymogram at baseline when diagnosed with chILD

    Time frame: 6 years

    (yes/no)

  14. Abnormal serum immunoglobulin at baseline when diagnosed with chILD

    Time frame: 6 years

    (yes/no)

  15. Abnormal serum creatinine at baseline when diagnosed with chILD

    Time frame: 6 years

    (yes/no)

  16. Abnormal blood urea nitrogen at baseline when diagnosed with chILD

    Time frame: 6 years

    (yes/no)

  17. Abnormal alanine transferase at baseline when diagnosed with chILD

    Time frame: 6 years

    (yes/no)

  18. Abnormal allergen at baseline when diagnosed with chILD

    Time frame: 6 years

    (yes/no)

  19. Recurrent hospitalization

    Time frame: 1 year after diagnosis

    yes:Hospitalization more than twice per year after diagnosed with chILD; no:Hospitalization less than three times per year after diagnosed with chILD;

Sponsors and collaborators

Lead sponsor

Children's Hospital of Fudan University

Other

Registry information

Important dates

Study start
2019
Primary completion
2026
Study completion
2026
First posted
Mar 11, 2019
Registry last updated
Mar 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.